Back to Knowledge Base
GLP-3RT
MetabolicRetatrutide (GLP-1/GIP/Glucagon Triple Receptor Agonist)
Overview
GLP-3RT (Retatrutide) is a novel triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. It is being investigated for obesity and type 2 diabetes, with early clinical trials showing significant weight loss results.
Mechanism of Action
Retatrutide activates three key metabolic receptors: GLP-1R (appetite suppression, insulin secretion), GIPR (enhanced incretin effect), and GCGR (increased energy expenditure, hepatic fat reduction). This triple mechanism may produce greater metabolic effects than single or dual agonists.
Research Contexts
Obesity / weight management • Type 2 diabetes • Metabolic syndrome • NAFLD/NASH • Cardiovascular risk reduction
Dosing (PepPal Protocol)
PepPal only publishes dosing from our vetted protocol PDFs. For peptides without an official PepPal protocol, see the Protocols page.
Dose escalation: Step 1: 1–2 mg/week (weeks 1–4). Step 2: 2–3 mg (weeks 4–8). Step 3: 3–4 mg (weeks 8–12). Step 4: 4–6 mg (weeks 12–16+). Advance only when current dose is comfortable for 2+ consecutive weeks.
Reconstitution Guide
Vial size: 10 mg, 20 mg, or 30 mg
Water volume: 1 mL per 10 mg of peptide
Concentration: 0.1 mg per unit (all vial sizes)
Draw up slowly along the vial wall — do not shake. 2 mg dose = 20 units, 4 mg dose = 40 units. Once weekly subcutaneous injection. Inject on the same day each week for consistency.
Storage Guidelines
Before reconstitution: Refrigerate at 2–8°C. Do not freeze.
After reconstitution: Refrigerate at 2–8°C. Use within 28 days.
Half-Life & Stability
Half-life: Approximately 6 days (once weekly dosing)
Stability: Generally stable when refrigerated. Slower titration typically means better long-term tolerability.
